{
    "nct_id": "NCT02810964",
    "official_title": "A Double-Blind Placebo-Controlled Trial of a Sulforaphane Nutraceutical to Reduce the Symptoms of Schizophrenia",
    "inclusion_criteria": "* Capacity for written informed consent\n* Age 18-65 years, inclusive\n* Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnosis of schizophrenia or schizoaffective disorder as determined by the Structured Clinical Interview for DSM-5 Disorders (SCID-5)\n* Currently an outpatient at time of screening\n* Residual psychotic symptoms of at least moderate severity as evidenced by a Positive and Negative Syndrome Scale (PANSS) total score of 60 or higher AND one or more of the following: one or more PANSS positive symptom scores of 4 or higher; OR containing at least three positive or negative items with scores of 3 or higher at the screening visit\n* Receiving antipsychotic medication for at least 8 weeks prior to enrolling in the study with no antipsychotic medication changes within the previous 21 days from visit 2 (week 0)\n* Conformance to PORT Treatment Recommendation about Maintenance Antipsychotic Medication Dose\n* Proficient in the English language\n* Participated previously in one of our screening studies\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Any clinically significant or unstable medical disorder as determined by the principal investigator and/or the study physician (e.g., HIV infection or other immunodeficiency condition (such as receiving chemotherapy), uncontrolled diabetes, congestive heart failure)\n* DSM-5 diagnosis of intellectual disability or comparable diagnoses determined by previous versions of the DSM\n* DSM-5 diagnosis of a moderate or severe substance use disorder, except for caffeine or tobacco, within the last three months prior to the screening visit. If the patient has a positive drug toxicity screen at the time of visit 1 (screening), further evaluation by the investigator will be done of the substance use to determine eligibility.\n* Any current use of a broccoli supplement (e.g., AvmacolÂ® or other health food broccoli supplement)\n* Participated in any investigational drug trial in the past 30 days prior to the screening visit\n* Pregnant, planning to become pregnant, or breastfeeding during the study period",
    "miscellaneous_criteria": ""
}